A5075350471- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Ferroptosis and cancer prognosis
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Liver Diseases and Immunity
- FOXO transcription factor regulation
- Esophageal Cancer Research and Treatment
- Cancer-related molecular mechanisms research
- Gallbladder and Bile Duct Disorders
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Diagnosis and treatment of tuberculosis
- Peptidase Inhibition and Analysis
- Cancer, Lipids, and Metabolism
- Vitamin C and Antioxidants Research
- MicroRNA in disease regulation
- Genetic factors in colorectal cancer
- Circular RNAs in diseases
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Peroxisome Proliferator-Activated Receptors
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Mechanisms and Therapy
Harbin Medical University
2016-2025
Third Affiliated Hospital of Harbin Medical University
2016-2025
Heilongjiang University
2025
Education Department of Heilongjiang Province
2020-2024
Nantong University
2022-2024
Heilongjiang Academy of Sciences
2019-2023
Affiliated Hospital of Hebei University
2011-2021
Heilongjiang Provincial Hospital
2015
Northeast Ohio Medical University
2010
University of California, Los Angeles
2003-2010
Farnesoid X receptor (FXR) plays an important role in maintaining bile acid and cholesterol homeostasis. Here we demonstrate that FXR also regulates glucose metabolism. Activation of by the synthetic agonist GW4064 or hepatic overexpression constitutively active adenovirus-mediated gene transfer significantly lowered blood levels both diabetic db/db wild-type mice. Consistent with these data, null mice exhibited intolerance insulin insensitivity. We further activation repressed gluconeogenic...
We assessed the efficacy and safety of camrelizumab [an anti-programmed death (PD-1) mAb] plus apatinib (a VEGFR-2 tyrosine kinase inhibitor) in patients with advanced hepatocellular carcinoma (HCC).This nonrandomized, open-label, multicenter, phase II study enrolled HCC who were treatment-naïve or refractory/intolerant to first-line targeted therapy. Patients received intravenous 200 mg (for bodyweight ≥50 kg) 3 mg/kg <50 every 2 weeks oral 250 daily. The primary endpoint was objective...
Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), 514 patients with treatment-naïve ESCC were randomized (1:1) to receive toripalimab or placebo in combination paclitaxel plus cisplatin (TP) every weeks up 6 cycles, followed by maintenance. At prespecified final analysis of progression-free survival (PFS), a significant improvement PFS observed arm over (hazard ratio...
To evaluate sintilimab versus placebo in combination with chemotherapy (cisplatin plus paclitaxel or cisplatin 5-fluorouracil) as first line treatment of unresectable locally advanced, recurrent, metastatic oesophageal squamous cell carcinoma.Multicentre, randomised, double blind, phase 3 trial.66 sites China and 13 outside between 14 December 2018 9 April 2021.659 adults (aged ≥18 years) advanced carcinoma who had not received systemic treatment.Participants were randomised 1:1 to receive...
Primary liver cancer, of which around 75-85% is hepatocellular carcinoma in China, the fourth most common malignancy and second leading cause tumor-related death, thereby posing a significant threat to life health Chinese people.Since publication Guidelines for Diagnosis Treatment Liver Cancer China June 2017, were updated by National Health Commission December 2019, additional high-quality evidence has emerged from researchers worldwide regarding diagnosis, staging, treatment that requires...
Circulating exosome holds great potentials as biomarker for diagnosis and prognosis of human cancers. Previously, we have applied small RNA sequencing to identify aberrantly expressed exosomal miRNAs candidates diagnostic markers in colon cancer patients. In this validation cohort, plasma derived miRNA was isolated from 50 early-stage patients matched healthy volunteers. Real-time qRT-PCR revealed that miR-125a-3p, miR-320c were significantly up-regulated exosomes the with early stage...
Immune checkpoint inhibitors (ICIs), including anti-PD-1 therapy, have limited efficacy in patients with microsatellite stable (MSS) colorectal cancer (CRC). Interleukin 17A (IL-17A) activity leads to a protumor microenvironment, dependent on its ability induce the production of inflammatory mediators, mobilize myeloid cells and reshape tumor environment. In present study, we aimed investigate role IL-17A resistance antitumor immunity explore feasibility anti-IL-17A combined therapy MSS CRC...
The nanocatalytic activity of nanozymes provides a vision for tumor treatment. However, the glutathione (GSH)-related antioxidant defense system (ADS) formed on basis excessive GSH in microenvironment limits its catalytic activity. Here, dendritic mesoporous silica nanoparticles (DMSNs) were employed as nanocarrier; ultrasmall Fe3O4 nanoparticles, Mn2+ ions, and glutaminase inhibitor Telaglenastat (CB-839) subsequently integrated into large mesopores DMSNs, forming DMSN/Fe3O4–Mn@CB-839...
Abstract The immunosuppression and immune escape of current immunotherapy result in low efficacy, ferroptosis is greatly restricted by the reactive oxygen species (ROS) production efficiency. Here, for first time a “closed‐loop” therapy based on photothermal enhancement stimulated each other multifunctional nanoplatform reported. This platform composed copper silicate iron mesoporous hollow nanospheres, followed situ growth Au nanoparticles loading an adjuvant resiquimod R848. laser...
Abstract Although immunogenic cell death (ICD) inducers evidently enhance the effectiveness of immunotherapy, their potential is increasingly restricted by development apoptosis resistance in tumor cells, poor immunogenicity, and low T‐cell immune responsiveness. In this study, for first time, piezoelectrically catalyzed Mg 2+ ‐doped hydroxyapatite (Mg‐HAP) nanoparticles, which are coated with a mesoporous silica layer loaded ONC201 as an agonist to specifically target receptor DR5 on...
This open-label phase II trial (NCT04542837) aimed to evaluate the efficacy and safety of KN046 combined with lenvatinib in patients advanced hepatocellular carcinoma (HCC), explore potential response biomarkers. Participants received 5 mg/kg every 3 weeks 12 or 8 mg once daily. The primary endpoints were safety, tolerability, dose-limiting toxicity (DLT), objective rate (ORR) according RECIST v1.1. A total fifty-five participants enrolled. results meet pre-specified endpoints. No DLT was...
Based on the observation that Fxr-/- mice exhibit a proatherogenic lipoprotein profile, we investigated role of FXR in development atherosclerosis.Administration western diet to or wild-type does not result significant atherosclerotic lesions. Consequently generated Ldlr-/- (DKO) and compared lesion with mice. After 16 weeks Western diet, en face analysis aorta indicated male DKO had reduced lesions as Plasma low-density cholesterol high-density levels were by 40% 50%, whereas triglyceride...
Abstract Owing to low immunogenicity‐induced immune escape and short‐term circulating responses, the efficiency of immunotherapy is unsatisfactory. Therefore, triggering immunogenic cell death establishing a long‐term, mutually reinforced treatment modality are urgent challenges. In this study, ultrathin CaBi 2 Nb O 9 nanosheets with tunable oxygen vacancies (abbreviated as CBNO‐OV1) prepared for synergistic necroptosis immunotherapy. The optimized vacancy concentration significantly...
Abstract Background Lenvatinib is widely used in treatment of unresectable hepatocellular carcinoma (uHCC), but the benefit its combination with immunotherapy needs to be verified. This study evaluated efficacy and safety tislelizumab plus lenvatinib systemic treatment-naïve patients uHCC. Methods In this multicenter, single-arm, phase 2 study, uHCC received 200 mg every three weeks (bodyweight ≥ 60 kg: 12 mg; < 8 once daily). Dose-limiting toxicities (DLTs) were run-in determine whether...
Abstract Background Although numerous studies have indicated that activated pyroptosis can enhance the efficacy of antitumour therapy in several tumours, precise mechanism colorectal cancer (CRC) remains unclear. Methods Pyroptosis CRC cells treated with agents was assessed using various techniques, including Western blotting, lactate dehydrogenase release assay and microscopy analysis. To uncover epigenetic mechanisms regulate NLRP3, chromatin changes NLRP3 promoter histone modifications...
PURPOSE Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression is an emerging biomarker in gastric cancer and gastroesophageal junction (GC). We assessed FGFR2b prevalence nearly 3,800 tumor samples as part of the prescreening process for a global phase III study patients with newly diagnosed advanced or metastatic GC. METHODS As June 28, 2024, 3,782 from prescreened 37 countries FORTITUDE-101 trial (ClinicalTrials.gov identifier: NCT05052801) were centrally tested...
We used mouse hepatic chromatin enriched with an FXR antibody and immunoprecipitation-sequencing (ChIP-seq) to evaluate binding on a genome-wide scale. This identified 1656 FXR-binding sites 10% were located within 2 kb of transcription start site which is much higher than predicted by random occurrence. A motif search uncovered canonical nuclear receptor IR-1 site, consistent in vitro DNA-binding studies reported previously. separate half-site for monomeric receptors such as LRH-1 was...